JBCHEPHARM Stock Overview
Manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
J. B. Chemicals & Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,953.80 |
| 52 Week High | ₹2,030.00 |
| 52 Week Low | ₹1,244.45 |
| Beta | -0.015 |
| 11 Month Change | 1.37% |
| 3 Month Change | 9.63% |
| 1 Year Change | 39.75% |
| 33 Year Change | 131.74% |
| 5 Year Change | 930.76% |
| Change since IPO | 2,486.96% |
Recent News & Updates
Most Shareholders Will Probably Agree With J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) CEO Compensation
Aug 15
J. B. Chemicals & Pharmaceuticals Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 11Recent updates
Most Shareholders Will Probably Agree With J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) CEO Compensation
Aug 15J. B. Chemicals & Pharmaceuticals Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 11These 4 Measures Indicate That J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Using Debt Reasonably Well
Jun 28J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Not Flying Under The Radar
Apr 19J. B. Chemicals & Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models
Feb 09J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Not Flying Under The Radar
Dec 22We Think J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Can Stay On Top Of Its Debt
Nov 29J. B. Chemicals & Pharmaceuticals' (NSE:JBCHEPHARM) Dividend Will Be Increased To ₹9.25
Aug 03J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Due To Pay A Dividend Of ₹8.50
Feb 11Is J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Using Too Much Debt?
Dec 03A Look At The Intrinsic Value Of J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM)
Sep 21J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Seems To Use Debt Quite Sensibly
Aug 03Estimating The Fair Value Of J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM)
Jun 15Does J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Have A Healthy Balance Sheet?
Mar 29J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Has Re-Affirmed Its Dividend Of ₹8.50
Feb 16With EPS Growth And More, J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Interesting
Jan 27J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Could Easily Take On More Debt
Nov 30Here's Why I Think J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Might Deserve Your Attention Today
Sep 24Shareholder Returns
| JBCHEPHARM | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 3.6% | 2.4% | 1.0% |
| 1Y | 39.7% | 60.9% | 44.7% |
Return vs Industry: JBCHEPHARM underperformed the Indian Pharmaceuticals industry which returned 60.9% over the past year.
Return vs Market: JBCHEPHARM underperformed the Indian Market which returned 44.7% over the past year.
Price Volatility
| JBCHEPHARM volatility | |
|---|---|
| JBCHEPHARM Average Weekly Movement | 3.4% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 9.8% |
| 10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: JBCHEPHARM has not had significant price volatility in the past 3 months.
Volatility Over Time: JBCHEPHARM's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 5,311 | Nikhil Chopra | www.jbpharma.com |
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company’s API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, cold rubs, eye drops, troches, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms.
J. B. Chemicals & Pharmaceuticals Limited Fundamentals Summary
| JBCHEPHARM fundamental statistics | |
|---|---|
| Market cap | ₹302.79b |
| Earnings (TTM) | ₹5.87b |
| Revenue (TTM) | ₹35.92b |
51.6x
P/E Ratio8.4x
P/S RatioIs JBCHEPHARM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JBCHEPHARM income statement (TTM) | |
|---|---|
| Revenue | ₹35.92b |
| Cost of Revenue | ₹12.44b |
| Gross Profit | ₹23.48b |
| Other Expenses | ₹17.61b |
| Earnings | ₹5.87b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 37.81 |
| Gross Margin | 65.37% |
| Net Profit Margin | 16.34% |
| Debt/Equity Ratio | 12.9% |
How did JBCHEPHARM perform over the long term?
See historical performance and comparison